Merck Beats 1q Profit Views With Tight Cost Controls

Merck posted an 18 percent jump in first-quarter income, beating Wall Street expectations, as reduced spending on marketing, administration and research easily offset lower medicine sales outside the U.S. The maker of Type 2 diabetes pill Januvia and cholesterol drugs Zetia and Vytorin is launching a new cycle of medicines for cancer and hepatitis C as brand-name or generic competition is hurting revenue from some older drugs. Frazier said Merck is looking for acquisitions, but not mega-deals, to bolster its pipeline of experimental drugs, while "actively addressing" key policy issues with the government and others, particularly drug prices and the need for corporate tax reform to make U.S.

Topics:  wall street   u.s    type   januvia   vytorin   frazier   zepatier   january   gilead sciences inc   harvoni   sovaldi   anderson   alzheimer   u.s    merck   drugs   hepatitis   posted   cholesterol   sales   government   experimental   
BING NEWS:
  • Walmart Inc. Q1 Profit Increases, Beats Estimates
    (RTTNews) - Walmart Inc. (WMT) announced earnings for its first quarter that increased from last year and beat the Street estimates. The company's earnings came in at $5.10 billion, or $0.63 per share ...
    05/16/2024 - 12:09 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More World News